Artiva Bio Stock
Artiva is an immunotherapy company with a mission to deliver to cancer patients highly effective cellular immunotherapies that are safe and immediately accessible. The company is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors.
Sign up today for more details and to buy or sell Artiva Bio Stock
Buy + SellArtiva Bio Funding
Gain insight into Artiva Bio funding rounds, the table below shows Artiva Bio capital raises and the dates of Artiva Bio financing history.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
Jul 10, 2020 | Series A | $43.44M | ||
Feb 22, 2021 | Series B | $120.00M |
See Valuations and Financials
Gain insights Into Artiva Bio Stock Valuation + Share Prices
Get started to view real-time data on Artiva Bio stock including most recent valuation and historical share price information.
Get StartedArtiva Bio Management Team
Director
Bong Koh
Director
Yvonne Yamanaka
Director
Elizabeth Hougen
Director
Edith A. Perez
CEO, President, Director
Fred Aslan
Director
Brian Daniels
Director
Laura Bessen
Director
Laura Stoppel
Co-Founder, Strategic Advisor
Peter Flynn
Director
James Park
Director
Linda Kozick
Chief Medical Officer
Thorsten Graef
Chief Technical Operations Officer
Christopher Horan
Director
Yong-Jun Huh
EVP, Chief Legal and People Officer
Jennifer Bush
Artiva Bio Major Investors
Venrock, Inc.
RTW Investments
Janus Henderson
Medivate Partners
5AM Ventures
EcoR1 Capital
Surveyor Capital - Citadel
venBio Partners LLC
Cormorant Asset Management
Logos Capital
Acuta Capital Partners
Wellington Management Company LLP
RA Capital Management LLC
Franklin Templeton
Green Cross Corp